Victor Velculescu

Personal Genome Diagnostics, Inc. provides cancer genome analysis to help researchers identify cancer-related genetic changes. The firm's product PDGx develops liquid biopsy technology that uses patient-specific tumor alterations to create a simple blood test that enables tumor detection and monitoring. It provides cancer genome analyses to oncology researchers, drug developers, clinicians and patients. The company was founded by Luis A. Diaz Jr. and Victor Velculescu in 2010 and is headquartered in Baltimore, MD.

Delfi Diagnostics, Inc. engages in the development of blood test for detection and interception of cancer. It uses artificial intelligence and whole genome sequencing to detect patterns of DNA fragmentation in the blood of patients with cancer. The company is headquartered in Baltimore, MD.

Delfi Diagnostics, Inc. engages in the development of blood test for detection and interception of cancer. It uses artificial intelligence and whole genome sequencing to detect patterns of DNA fragmentation in the blood of patients with cancer. The company is headquartered in Baltimore, MD.

Delfi Diagnostics, Inc. engages in the development of blood test for detection and interception of cancer. It uses artificial intelligence and whole genome sequencing to detect patterns of DNA fragmentation in the blood of patients with cancer. The company is headquartered in Baltimore, MD.

Delfi Diagnostics, Inc. engages in the development of blood test for detection and interception of cancer. It uses artificial intelligence and whole genome sequencing to detect patterns of DNA fragmentation in the blood of patients with cancer. The company is headquartered in Baltimore, MD.

Delfi Diagnostics, Inc. engages in the development of blood test for detection and interception of cancer. It uses artificial intelligence and whole genome sequencing to detect patterns of DNA fragmentation in the blood of patients with cancer. The company is headquartered in Baltimore, MD.

Delfi Diagnostics, Inc. engages in the development of blood test for detection and interception of cancer. It uses artificial intelligence and whole genome sequencing to detect patterns of DNA fragmentation in the blood of patients with cancer. The company is headquartered in Baltimore, MD.

Personal Genome Diagnostics, Inc. provides cancer genome analysis to help researchers identify cancer-related genetic changes. The firm's product PDGx develops liquid biopsy technology that uses patient-specific tumor alterations to create a simple blood test that enables tumor detection and monitoring. It provides cancer genome analyses to oncology researchers, drug developers, clinicians and patients. The company was founded by Luis A. Diaz Jr. and Victor Velculescu in 2010 and is headquartered in Baltimore, MD.

Delfi Diagnostics, Inc. engages in the development of blood test for detection and interception of cancer. It uses artificial intelligence and whole genome sequencing to detect patterns of DNA fragmentation in the blood of patients with cancer. The company is headquartered in Baltimore, MD.

Personal Genome Diagnostics, Inc. provides cancer genome analysis to help researchers identify cancer-related genetic changes. The firm's product PDGx develops liquid biopsy technology that uses patient-specific tumor alterations to create a simple blood test that enables tumor detection and monitoring. It provides cancer genome analyses to oncology researchers, drug developers, clinicians and patients. The company was founded by Luis A. Diaz Jr. and Victor Velculescu in 2010 and is headquartered in Baltimore, MD.